Successful 13‐year ongoing remission with <scp>C5</scp> inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Successful 13‐year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome

Published:2024-08-23 Issue: Volume: Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Mostafa Mariam A.¹²^ORCID,Zand Martin³,Taylor Jeremy³,Kouides Peter⁴

Affiliation:

1. Rochester General Hospital Rochester New York USA

2. Faculty of Medicine Ain Shams University Cairo Egypt

3. University of Rochester Rochester New York USA

4. Roswell Park Memorial Cancer Institute, Rochester General Hospital University of Rochester Rochester New York USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27461

Reference10 articles.

1. Atypical Hemolytic–Uremic Syndrome

2. Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome

3. Ravulizumab in Preemptive Living Donor Kidney Transplantation in Hereditary Atypical Hemolytic Uremic Syndrome

4. First Report on Successful Conversion of Long-Term Treatment of Recurrent Atypical Hemolytic Uremic Syndrome With Eculizumab to Ravulizumab in a Renal Transplant Patient

5. Atypical hemolytic uremic syndrome;Afshar‐Kharghan V;Hematology Am Soc Hematol Educ Program,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP